RESUMEN
N,N'-Diaryl ureas have recently emerged as a new antischistosomal chemotype. We now describe physicochemical profiling, in vitro ADME, plasma exposure, and ex vivo and in vivo activities against Schistosoma mansoni for twenty new N,N'-diaryl ureas designed primarily to increase aqueous solubility, but also to maximize structural diversity. Replacement of one of the 4-fluoro-3-trifluoromethylphenyl substructures of lead N,N'-diaryl urea 1 with azaheterocycles and benzoic acids, benzamides, or benzonitriles decreased lipophilicity, and in most cases, increased aqueous solubility. There was no clear relationship between lipophilicity and metabolic stability, although all compounds with 3-trifluoromethyl-4-pyridyl substructures were metabolically stable. N,N'-diaryl ureas containing 4-fluoro-3-trifluoromethylphenyl, 3-trifluoromethyl-4-pyridyl, 2,2-difluorobenzodioxole, or 4-benzonitrile substructures had high activity against ex vivo S. mansoni and relatively low cytotoxicity. N,N-diaryl ureas with 3-trifluoromethyl-4-pyridyl and 2,2-difluorobenzodioxole substructures had the highest exposures whereas those with 4-fluoro-3-trifluoromethylphenyl substructures had the best in vivo antischistosomal activities. There was no direct correlation between compound exposure and in vivo activity.
Asunto(s)
Compuestos de Fenilurea/farmacología , Esquistosomicidas/farmacología , Animales , Línea Celular , Humanos , Masculino , Ratones , Microsomas Hepáticos/metabolismo , Estructura Molecular , Pruebas de Sensibilidad Parasitaria , Compuestos de Fenilurea/síntesis química , Compuestos de Fenilurea/química , Compuestos de Fenilurea/toxicidad , Schistosoma mansoni/efectos de los fármacos , Esquistosomicidas/síntesis química , Esquistosomicidas/química , Esquistosomicidas/toxicidad , Solubilidad , Relación Estructura-ActividadRESUMEN
To better control gastrointestinal nematode infections in humans and animals, it is important to understand the strategies used by these parasites to modulate the host immune system. In this regard, molecules released by parasites have been attributed crucially important roles in host-parasite negotiations. We characterized the excretory/secretory (E/S) microRNA (miRNA) and protein profiles from the mouse gastrointestinal nematode parasite Trichuris muris. Released miRNAs were subjected to miRNA sequencing and E/S proteins were analysed by mass spectrometry. Fourteen miRNAs were identified in T. muris exosome-like vesicles, as well as 73 proteins of nematode origin, 11 of which were unique to this study. Comparison with published nematode protein secretomes revealed high conservation at the functional level.
Asunto(s)
Exosomas/química , Proteínas del Helminto/análisis , MicroARNs/aislamiento & purificación , Trichuris/metabolismo , Animales , Medios de Cultivo/química , Proteínas del Helminto/genética , Proteínas del Helminto/inmunología , Proteínas del Helminto/fisiología , Proteómica , Reproducibilidad de los Resultados , Trichuris/genética , Trichuris/inmunologíaRESUMEN
The current treatments against Trichuris trichiura, albendazole and mebendazole, are only poorly efficacious. Therefore, combination chemotherapy was recommended for treating soil-transmitted helminthiasis. Albendazole-mebendazole and albendazole-oxantel pamoate have shown promising results in clinical trials. However, in vitro and in vivo drug interaction studies should be performed before their simultaneous treatment can be recommended. Inhibition of human recombinant cytochromes P450 (CYPs) CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 was tested by exposure to albendazole, albendazole sulfoxide, mebendazole, and oxantel pamoate, as well as albendazole-mebendazole, albendazole sulfoxide-mebendazole, albendazole-oxantel pamoate, and albendazole sulfoxide-oxantel pamoate. A high-pressure liquid chromatography (HPLC)-UV/visible spectroscopy method was developed and validated for simultaneous quantification of albendazole sulfoxide, albendazole sulfone, mebendazole, and oxantel pamoate in plasma. Albendazole, mebendazole, oxantel pamoate, albendazole-mebendazole, and albendazole-oxantel pamoate were orally applied to rats (100 mg/kg) and pharmacokinetic parameters calculated. CYP1A2 showed a 2.6-fold increased inhibition by albendazole-oxantel pamoate (50% inhibitory concentration [IC50] = 3.1 µM) and a 3.9-fold increased inhibition by albendazole sulfoxide-mebendazole (IC50 = 3.8 µM) compared to the single drugs. In rats, mebendazole's area under the concentration-time curve (AUC) and maximal plasma concentration (Cmax) were augmented 3.5- and 2.8-fold, respectively (P = 0.02 for both) when coadministered with albendazole compared to mebendazole alone. Albendazole sulfone was slightly affected by albendazole-mebendazole, displaying a 1.3-fold-elevated AUC compared to albendazole alone. Oxantel pamoate could not be quantified, translating to a bioavailability below 0.025% in rats. Elevated plasma levels of albendazole sulfoxide, albendazole sulfone, and mebendazole in coadministrations are probably not mediated by CYP-based drug-drug interaction. Even though this study indicates that it is safe to coadminister albendazole-oxantel pamoate and albendazole-mebendazole, human pharmacokinetic studies are recommended.
Asunto(s)
Albendazol/farmacocinética , Antihelmínticos/farmacocinética , Mebendazol/farmacocinética , Pamoato de Pirantel/análogos & derivados , Tricuriasis/tratamiento farmacológico , Trichuris/efectos de los fármacos , Administración Oral , Albendazol/sangre , Animales , Antihelmínticos/sangre , Área Bajo la Curva , Sistema Enzimático del Citocromo P-450/genética , Sistema Enzimático del Citocromo P-450/metabolismo , Combinación de Medicamentos , Interacciones Farmacológicas , Expresión Génica , Isoenzimas/genética , Isoenzimas/metabolismo , Mebendazol/sangre , Ratones , Pruebas de Sensibilidad Microbiana , Pamoato de Pirantel/sangre , Pamoato de Pirantel/farmacocinética , Ratas , Ratas Sprague-Dawley , Suelo/parasitología , Tricuriasis/sangre , Tricuriasis/parasitología , Tricuriasis/transmisión , Trichuris/crecimiento & desarrolloRESUMEN
One of the major neglected tropical diseases, schistosomiasis, is currently treated and controlled with a single drug, praziquantel. The quest for an alternative drug is fueled by the lack of activity of praziquantel against juvenile Schistosoma worms and the fear of emerging resistance. The synthetic ozonide OZ418 has shown high activity against Schistosoma mansoni, S. haematobium, and S. japonicum in vivo, but its drug disposition remains unknown. To bridge this gap, our study determined the basic pharmacokinetic (PK) parameters of a single oral dose (400 mg/kg of body weight) of OZ418 in uninfected mice. First, a simple liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to quantify OZ418 concentrations in mouse plasma was successfully developed and validated according to U.S. FDA guidelines. This method proved to be selective, accurate (93 to 103%), precise (5 to 16%), and devoid of significant matrix effects (90 to 102%) and provided excellent recovery (101 to 102%). A median peak concentration of 190 (range, 185 to 231) µg/ml was reached at 2 h (2 to 3 h) posttreatment. A naive pooled noncompartmental PK analysis estimated a mean area under the plasma concentration-versus-time curve (AUC) of 9,303 µg h/ml (7,039.2 to 11,908.5 µg h/ml) and a half-life of 38.7 h (20 to 64.6 h). Thus, the OZ418 level in plasma remained well above its in vitro 50% inhibitory concentrations (IC50s) of 27.4 µg/ml (adult S. mansoni worms at 72 h) for at least 75 h. Consistently, OZ418 degraded little in plasma at 37°C (<20% in 121 h) and weakly inhibited cytochrome P450 (CYP450) metabolism (IC50 of 37 to 144 µM). Our results provide a first insight into the disposition of OZ418, paving the way for further studies of its biological fate and effect.
Asunto(s)
Inhibidores Enzimáticos del Citocromo P-450/farmacocinética , Compuestos Heterocíclicos con 1 Anillo/farmacocinética , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis mansoni/tratamiento farmacológico , Esquistosomicidas/farmacocinética , Compuestos de Espiro/farmacocinética , Administración Oral , Animales , Cromatografía Liquida , Sistema Enzimático del Citocromo P-450/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Femenino , Semivida , Ratones , Esquistosomiasis mansoni/parasitología , Espectrometría de Masas en TándemRESUMEN
Praziquantel (PZQ) is the only drug available for the treatment of schistosomiasis, and since its large-scale use might be associated with the onset of resistance, new antischistosomal drugs should be developed. A series of 26 synthetic tetraazamacrocyclic derivatives and their metal complexes were synthesized, characterized, and screened for antischistosomal activity by application of a phased screening program. The compounds were first screened against newly transformed schistosomula (NTS) of harvested Schistosoma mansoni cercariae, then against adult worms, and finally, in vivo using the mouse model of S. mansoni infection. At a concentration of 33 µM, incubation with a total of 12 compounds resulted in the mortality of NTS at the 62% to 100% level. Five of these showing 100% inhibition of viability of NTS at 10 µM were selected for further screening for determination of the 50 inhibitory concentrations (IC50s) against both NTS and adult worms. Against NTS, all 5 compounds showed IC50s comparable to the IC50 of the standard drug, PZQ (0.87 to 9.65 µM for the 5 compounds versus 2.20 µM for PZQ). Three of these, which are the bisquinoline derivative of cyclen and its Fe(2+) and Mn(2+) complexes, showed micromolar IC50s (1.62 µM, 1.34 µM, and 4.12 µM, respectively, versus 0.10 µM for PZQ) against adult worms. In vivo, the worm burden reductions were 12.3%, 88.4%, and 74.5%, respectively, at a single oral dose of 400 mg/kg of body weight. The Fe(2+) complex exhibited activity in vivo comparable to that of PZQ, pointing to the discovery of a novel drug lead for schistosomiasis.
Asunto(s)
Complejos de Coordinación/farmacología , Compuestos Heterocíclicos/farmacología , Quinolinas/farmacología , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis mansoni/tratamiento farmacológico , Esquistosomicidas/farmacología , Animales , Cationes Bivalentes , Cercarias/efectos de los fármacos , Cercarias/crecimiento & desarrollo , Complejos de Coordinación/síntesis química , Descubrimiento de Drogas , Femenino , Compuestos Heterocíclicos/síntesis química , Concentración 50 Inhibidora , Hierro/química , Manganeso/química , Ratones , Compuestos Organometálicos , Praziquantel/farmacología , Quinolinas/síntesis química , Schistosoma mansoni/crecimiento & desarrollo , Esquistosomiasis mansoni/parasitología , Esquistosomicidas/síntesis química , Relación Estructura-ActividadRESUMEN
OBJECTIVES: Praziquantel is the only drug available for the treatment of schistosomiasis and the state of the exhausted drug discovery pipeline is alarming. We restarted investigations on the abandoned antischistosomal Ro 13-3978, an aryl hydantoin discovered in the early 1980s by Hoffmann La-Roche. METHODS: Newly transformed schistosomula and adult Schistosoma mansoni were studied in the presence of Ro 13-3978 in vitro. The metabolic stability of Ro 13-3978 was determined in vitro using human and mouse liver S9 fractions. Dose-response relationship, stage specificity, hepatic shift and scanning electron microscopy studies were carried out in S. mansoni-infected mice. In addition, efficacy experiments were conducted in rodents infected with Echinostoma caproni and Fasciola hepatica as well as in S. mansoni-infected immunocompromised nude (Foxn1(nu)) mice. RESULTS: Ro 13-3978 showed minor in vitro activity and no damage to the tegument was found. No cytotoxicity was detected for Ro 13-3978. Ro 13-3978 was metabolically stable. ED50 values of 138.9 and 14.6 mg/kg were calculated for the treatment of juvenile and adult S. mansoni infections, respectively, with a single oral dose of Ro 13-3978. SEM studies revealed severe damage to the worms 48 h post-treatment of infected mice. A single oral dose of Ro 13-3978 (100 mg/kg) administered to S. mansoni-infected (Foxn1(nu)) mice reduced the worm burden by 88%. Ro 13-3978 was not active against E. caproni and F. hepatica in vivo. CONCLUSIONS: Ro 13-3978 has excellent antischistosomal properties in vivo. Structure-activity relationship studies with the aryl hydantoins have been launched in order to elucidate active pharmacophores, further investigate the mechanism of action and to identify a derivative with minimal antiandrogenic effects.
Asunto(s)
Antihelmínticos/farmacología , Hidantoínas/farmacología , Schistosoma mansoni/efectos de los fármacos , Animales , Antihelmínticos/administración & dosificación , Modelos Animales de Enfermedad , Echinostoma/efectos de los fármacos , Echinostoma/ultraestructura , Equinostomiasis/tratamiento farmacológico , Equinostomiasis/parasitología , Fasciola hepatica/efectos de los fármacos , Fasciola hepatica/ultraestructura , Fascioliasis/tratamiento farmacológico , Fascioliasis/parasitología , Femenino , Hidantoínas/administración & dosificación , Ratones , Microscopía Electrónica de Transmisión , Ratas , Schistosoma mansoni/ultraestructura , Esquistosomiasis mansoni/tratamiento farmacológico , Esquistosomiasis mansoni/parasitología , Relación Estructura-Actividad , Resultado del TratamientoRESUMEN
We studied the antischistosomal activity of betulin, betulinic acid and its 9 triphenylphosphonium derivatives characterized by a covalently linkage of the hydrophobic fragment of triterpenoid at C(2)- or C(30)-position with the triphenylphosphonium moiety via a hydrocarbon bridge. The triphenylphosphonium salts showed in vitro antischistosomal activity against newly transformed schistosomula (NTS) and adult worms of Schistosoma mansoni at low micromolar concentrations. In contrast betulin and betulinic acid were inactive against NTS and adult S. mansoni. Of the 9 triphenylphosphonium derivatives tested, the allyl salts 10 (IC50 of 0.76 µg/mL) and 11 (IC50 of 0.64 µg/mL) demonstrated the highest antischistosomal activity against adult S. mansoni. Low worm burden reductions of 22% were observed in vivo for these two compounds. In conclusion, triphenylphosphonium derivatives were obtained from available natural betulin by simple transformations, rendering it practical and useful for large scale application. However, further structural modifications are necessary to translate the promising antischistosomal in vitro activities into in vivo.
Asunto(s)
Antihelmínticos/química , Antihelmínticos/uso terapéutico , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis mansoni/tratamiento farmacológico , Triterpenos/química , Triterpenos/uso terapéutico , Animales , Antihelmínticos/síntesis química , Antihelmínticos/farmacología , Femenino , Humanos , Ratones , Compuestos Organofosforados/síntesis química , Compuestos Organofosforados/química , Compuestos Organofosforados/farmacología , Compuestos Organofosforados/uso terapéutico , Triterpenos Pentacíclicos , Esquistosomiasis mansoni/parasitología , Triterpenos/síntesis química , Triterpenos/farmacología , Ácido BetulínicoRESUMEN
Chronic Schistosoma mansoni infections lead to severe tissue destruction of the gut wall and liver and can influence drug disposition. This study aimed to investigate the impact of a chronic S. mansoni infection on the pharmacokinetic (PK) parameters of two promising antischistosomal lead candidates (mefloquine and enpiroline) in mice. Studies were conducted in two different mouse cohorts (S. mansoni-infected and uninfected mice) for both drugs. Plasma samples were collected at various time points after oral treatment (200 mg/kg of body weight) with study drugs. A high-performance liquid chromatography (HPLC) method was validated to analyze enpiroline and mefloquine in plasma. Livers and intestines were collected from infected animals to determine the onset of action, hepatic shift, and worm burden reduction. Following mefloquine administration, hepatic shifting and significant worm burden reductions (79.2%) were observed after 72 h. At 1 week posttreatment with enpiroline, the majority of worms had migrated to the liver and significant worm burden reductions were observed (93.1%). The HPLC method was selective, accurate (87.8 to 111.4%), and precise (<10%) for the analysis of both drugs in plasma samples. The PK profiles revealed increased values for half-life (t1/2) and area under the concentration-time curve (AUC) for both drugs in infected animals compared to the t1/2 and AUC values in uninfected animals. Considerable changes were observed for mefloquine, with a 5-fold increase of t1/2 (182.7 h versus 33.6 h) and 2-fold increase of AUC (1,116,517.8 ng · h/ml versus 522,409.1 ng · h/ml). S. mansoni infections in mice influence the PK profiles of enpiroline and mefloquine, leading to delayed clearance. Our data confirm that drug disposition should be carefully studied in schistosomiasis patients.
Asunto(s)
Antihelmínticos/farmacocinética , Mefloquina/farmacocinética , Piridinas/farmacocinética , Enfermedades de los Roedores/tratamiento farmacológico , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis mansoni/veterinaria , Administración Oral , Animales , Antihelmínticos/sangre , Antihelmínticos/farmacología , Enfermedad Crónica , Relación Dosis-Respuesta a Droga , Femenino , Semivida , Intestinos/efectos de los fármacos , Intestinos/parasitología , Hígado/efectos de los fármacos , Hígado/parasitología , Mefloquina/sangre , Mefloquina/farmacología , Ratones , Piridinas/sangre , Piridinas/farmacología , Enfermedades de los Roedores/sangre , Enfermedades de los Roedores/parasitología , Schistosoma mansoni/fisiología , Esquistosomiasis mansoni/sangre , Esquistosomiasis mansoni/tratamiento farmacológico , Esquistosomiasis mansoni/parasitologíaRESUMEN
We evaluated the in vivo antischistosomal activities of 11 structurally diverse synthetic peroxides. Of all compounds tested, ozonide (1,2,4-trioxolane) OZ418 had the highest activity against adult Schistosoma mansoni, with total and female worm burden reductions of 80 and 90% (P < 0.05), respectively. Furthermore, treatment of S. haematobium-infected mice with OZ418 reduced the total worm burden by 86%. In conclusion, OZ418 is a promising antischistosomal lead compound.
Asunto(s)
Antihelmínticos/uso terapéutico , Compuestos Heterocíclicos/uso terapéutico , Schistosoma haematobium/efectos de los fármacos , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis Urinaria/tratamiento farmacológico , Esquistosomiasis mansoni/tratamiento farmacológico , Animales , Antihelmínticos/administración & dosificación , Antihelmínticos/química , Femenino , Compuestos Heterocíclicos/administración & dosificación , Compuestos Heterocíclicos/química , Ratones , Esquistosomiasis Urinaria/parasitología , Esquistosomiasis mansoni/parasitología , Resultado del TratamientoRESUMEN
Natural products play an important role in the discovery and development of new pharmaceuticals. In the present study, we assessed the anthelmintic properties of medicinal plants used in Cote d'Ivoire. Ethanolic extracts from 50 medicinal plants were tested in vitro against trematodes (Echinostoma caproni, Schistosoma mansoni) and nematodes (Ancylostoma ceylanicum, Heligmosomoides bakeri, Trichuris muris). Active extracts were evaluated for their cytotoxicity and followed up in vivo in mice harbouring adult S. mansoni, E. caproni and T. muris at single oral doses of 400 or 800 mg/kg. All extracts tested were active against at least one helminths species. Ten of the 65 extracts tested (15.4%) in vitro revealed activity against all helminths tested. Of 65 extracts tested in vitro at a concentration of 2 mg/ml, all caused death of schistosomula and 34.4% and 39.1% were lethal against adult S. mansoni and E. caproni 72 h post-incubation, respectively. The highest activity against A. ceylanicum in vitro was observed with Sclerocarya birrea at 2 mg/ml, which resulted in death of adult worms and inhibition of activity of third-stage larvae (L3). Of the extracts, 41.5% completely inhibited movement of H. bakeri L3 at minimal lethal concentration (MLC) values of 20-200 µg/ml 48 h post-incubation, and 15.4% paralysed adult H. bakeri at 200 µg/ml 72 h after incubation. Of the extracts, 19% resulted in death of adult T. muris at MLC values of 10-100 µg/ml. In vivo, none of the extracts tested revealed activity against E. caproni. Olax subscorpioidea achieved total and female worm burden reductions of 60% and 84%, respectively in S. mansoni-infected mice. Combretum mucronatum was the most active extracts in vivo against T. muris with a worm burden reduction of 85.3%. In conclusion, several of the medicinal plants used in Côte d'Ivoire are active against different helminths, hence might play a role in the treatment of helminthiases. Further studies are necessary to isolate the active components from these extracts.
Asunto(s)
Antihelmínticos/farmacología , Nematodos/efectos de los fármacos , Extractos Vegetales/farmacología , Plantas Medicinales/química , Trematodos/efectos de los fármacos , Animales , Antihelmínticos/efectos adversos , Antihelmínticos/aislamiento & purificación , Antihelmínticos/uso terapéutico , Bioensayo , Côte d'Ivoire , Modelos Animales de Enfermedad , Femenino , Helmintiasis/tratamiento farmacológico , Helmintiasis/parasitología , Masculino , Ratones , Extractos Vegetales/efectos adversos , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/uso terapéutico , Análisis de SupervivenciaRESUMEN
OBJECTIVES: Mefloquine has interesting antischistosomal properties, hence it might be an attractive partner drug for combination treatment with praziquantel. The aim of this study was to evaluate activities of mefloquine/praziquantel combinations against Schistosoma mansoni in vitro and in vivo. METHODS: Dose-response relationships were established following exposure of adult S. mansoni to mefloquine, praziquantel and fixed dose combinations of mefloquine/praziquantel in vitro. S. mansoni-infected mice were treated orally with selected doses of single drugs and drug combinations 7 weeks post-infection. RESULTS: We calculated in vitro LC(50) values of 0.024 and 1.9 µg/mL for praziquantel and mefloquine, respectively. Mefloquine/praziquantel combinations showed synergistic effects, with combination index (CI) values <1 when adult S. mansoni were simultaneously incubated with both drugs in vitro. Reduced viabilities were also observed when schistosomes were first exposed to mefloquine followed by praziquantel in vitro. ED(50)s of 62 mg/kg and 172 mg/kg were determined for mefloquine and praziquantel against adult S. mansoni in vivo, respectively. Combinations of praziquantel (50 or 100 mg/kg) followed the next day by mefloquine (50 or 100 mg/kg) treatment revealed only moderate total worm burden reductions of 47.8%-54.7%. On the other hand, when both drugs (100 mg/kg each) were either given simultaneously or mefloquine was given prior to praziquantel, high total and female worm burden reductions of 86.0%-93.1% were observed. For the later treatment regimen, synergistic effects (CI < 1) were calculated when mefloquine and praziquantel were combined using a fixed dose ratio based on their ED(50)s. CONCLUSIONS: Combinations of mefloquine and praziquantel may have clinical utility in the treatment of schistosomiasis.
Asunto(s)
Antihelmínticos/administración & dosificación , Sinergismo Farmacológico , Mefloquina/administración & dosificación , Praziquantel/administración & dosificación , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis mansoni/tratamiento farmacológico , Administración Oral , Animales , Antihelmínticos/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada/métodos , Femenino , Ratones , Praziquantel/farmacología , Enfermedades de los Roedores/tratamiento farmacológico , Resultado del TratamientoRESUMEN
Dispiro 1,2,4-trioxanes and 1,2,4,5-tetraoxanes had superior efficacy against Fasciola hepatica than the corresponding ozonides (1,2,4-trioxolanes). For highest efficacy, spiroadamantane and carboxymethyl substructures were required. Three compounds completely cured F. hepatica-infected mice at single oral doses of 50mg/kg and two were partially curative at single doses of 25mg/kg.
Asunto(s)
Fasciola hepatica/efectos de los fármacos , Compuestos Heterocíclicos/farmacología , Compuestos de Espiro/farmacología , Tetraoxanos/farmacología , Animales , Relación Dosis-Respuesta a Droga , Compuestos Heterocíclicos/síntesis química , Compuestos Heterocíclicos/química , Ratones , Estructura Molecular , Compuestos de Espiro/síntesis química , Compuestos de Espiro/química , Estereoisomerismo , Tetraoxanos/síntesis química , Tetraoxanos/químicaRESUMEN
The cyclooctadepsipeptide PF1022A derived from the fungus, Mycelia sterilia, is characterized by a broad spectrum of activity against different parasitic gastrointestinal nematodes of livestock. In the present work the anthelmintic activity of PF1022A against Heligmosomoides bakeri, a widely used laboratory model was studied. Albendazole, ivermectin and levamisole served as reference. In vitro, PF1022A showed low activity on embryonation but significantly inhibited egg hatch (10 and 100 µg/ml), whereas albendazole (10 and 100 µg/ml) revealed statistically significant inhibitions of both embryonation and egg hatch. PF1022A (1-100 µg/ml) completely inhibited larval movement at most examination points. Comparable significant anthelmintic activity on the larval stages of H. bakeri was observed with levamisole (48-100%), while slightly lower activities were observed with ivermectin (20-92%) and albendazole (0-87%) at 1-100 µg/ml. PF1022A and levamisole significantly inhibited motility and egg release of adult worms, while albendazole and ivermectin failed to demonstrate activity. Significant worm burden reductions were achieved with PF1022A, levamisole and ivermectin in vivo. For example, at 0·125 mg/kg PF1022A a worm burden reduction of 91·8% was observed. The use of drug combinations did not further enhance the in vitro and in vivo activity of PF1022A. In conclusion, further investigations are warranted with PF1022A, as the drug is characterized by significant larvicidal and nematocidal activity in vitro and in vivo.
Asunto(s)
Antihelmínticos/farmacología , Depsipéptidos/farmacología , Heligmosomatoidea/efectos de los fármacos , Larva/efectos de los fármacos , Infecciones por Strongylida/tratamiento farmacológico , Albendazol/farmacología , Animales , Antihelmínticos/química , Antihelmínticos/uso terapéutico , Depsipéptidos/química , Depsipéptidos/uso terapéutico , Combinación de Medicamentos , Heces/parasitología , Femenino , Heligmosomatoidea/crecimiento & desarrollo , Ivermectina/farmacología , Larva/crecimiento & desarrollo , Levamisol/farmacología , Ganado/parasitología , Ratones , Ratones Endogámicos , Recuento de Huevos de Parásitos , Infecciones por Strongylida/parasitología , Resultado del TratamientoRESUMEN
OBJECTIVES: The antischistosomal properties of the marketed antiandrogens bicalutamide, flutamide, nilutamide and cyproterone acetate were studied both in vivo and in vitro. METHODS: Schistosoma mansoni-infected mice were treated orally with 50-400 mg/kg of the antiandrogens 3 and 7 weeks post-infection. In addition, three drug combinations of nilutamide and praziquantel (200/100, 100/100 and 100/50 mg/kg) were administered to mice harbouring adult S. mansoni. Drug effects were also monitored in vitro following exposure to antiandrogen concentrations of 1, 10 and 100 microg/mL. RESULTS: Low total worm burden reductions (5%-37%) and low to moderate female worm burden reductions (13%-75%) were achieved with the antiandrogens in the S. mansoni juvenile infection model. While flutamide and cyproterone acetate lacked activity against adult S. mansoni in vivo, low to moderate total and female worm burden reductions (0%-47%) were observed with bicalutamide. The highest total and female worm burden reductions (85% and 71%, respectively) (P < 0.001) were documented following a single 400 mg/kg dose of nilutamide. Statistically significant total (91%) and female (85%) worm burden reductions were achieved with the combination of nilutamide (200 mg/kg) and praziquantel (100 mg/kg). Schistosomes incubated with 100 microg/mL cyproterone acetate in vitro died after 15 h. Incubation with bicalutamide, nilutamide and flutamide at 100 microg/mL resulted in decreased movement of S. mansoni adults. CONCLUSIONS: Our data indicate that the hydantoin derivative nilutamide has interesting antischistosomal properties, confirming previous results of schistosomicidal activities of this drug class.
Asunto(s)
Antagonistas de Andrógenos/farmacología , Antihelmínticos/farmacología , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis mansoni/tratamiento farmacológico , Administración Oral , Antagonistas de Andrógenos/administración & dosificación , Animales , Antihelmínticos/administración & dosificación , Modelos Animales de Enfermedad , Femenino , Imidazolidinas/administración & dosificación , Imidazolidinas/farmacología , Masculino , Ratones , Praziquantel/administración & dosificación , Praziquantel/farmacologíaRESUMEN
Six amide and four urea derivatives of praziquantel were synthesized and tested for antischistosomal activity against juvenile and adults stages of Schistosoma mansoni in infected mice. Only one of these had significant activity against adult worms, but, unlike praziquantel, six of these had low to modest activity against juvenile worms. A praziquantel ketone derivative had the best combination of activity against juveniles and adults, but it had no effect on the motility of adult S. mansoni in ex vivo culture. Cytochrome P450 metabolic stability data support the hypothesis that the major trans-cyclohexanol metabolite of praziquantel plays an important role in the antischistosomal activity of this drug.
Asunto(s)
Antihelmínticos/farmacología , Praziquantel/farmacología , Schistosoma mansoni/efectos de los fármacos , Animales , RatonesRESUMEN
We compared the sedimentation and FLOTAC techniques for the detection and quantification of Fasciola hepatica eggs in faecal samples obtained from 120 experimentally-infected rats before intervention, and in 42 rats after drug administration. Additionally, the average time for a single test was determined. A single FLOTAC showed a higher sensitivity (92.6%) than 2, 4 and 8 sedimentation readings (63.0-85.2%) for detecting F. hepatica eggs in rat faeces post-treatment. On average, it took 21 min to prepare and examine a single FLOTAC, whereas 114 min were needed for the sedimentation method including the reading of 8 slides. In both treated and untreated rats, the sedimentation method resulted in higher mean faecal egg counts (FECs) than FLOTAC (P<0.05). In view of the high sensitivity and efficiency, the FLOTAC technique holds promise for experimental work in the F. hepatica-rat model. Additional research is needed to determine the reasons for the observed differences in FECs.
Asunto(s)
Fasciola hepatica/aislamiento & purificación , Fascioliasis/diagnóstico , Heces/parasitología , Recuento de Huevos de Parásitos/métodos , Animales , Antihelmínticos/farmacología , Antihelmínticos/uso terapéutico , Fasciola hepatica/efectos de los fármacos , Fascioliasis/tratamiento farmacológico , Fascioliasis/parasitología , Femenino , Ratas , Ratas Wistar , Sensibilidad y Especificidad , Factores de TiempoRESUMEN
BACKGROUND: Praziquantel (PZQ) is the mainstay of schistosomiasis control and has been successfully used for decades. However, its mechanism of action is not fully understood. While the majority of studies have been conducted on Schistosoma mansoni, it is not known which enantiomer, R- or S-praziquantel (R-/S-PZQ), is responsible for the activity on Schistosoma haematobium. METHODS: In vitro and in vivo studies were conducted to evaluate the activity of R- and S-PZQ, racemic PZQ and the main human metabolite, namely trans-4-OH-PZQ, on S. haematobium. IC50 values on adult S. haematobium were determined in vitro. Dose-response relationship studies were performed in golden Syrian hamsters, harbouring a chronic S. haematobium infection. RESULTS: R-PZQ displayed the highest activity against adult worms in vitro, revealing an IC50 of 0.007 µg/ml at 4 h and 0.01 µg/ml at 72 h. In contrast, S-PZQ was 501× less active (eudysmic ratio at 4 h), with an IC50 of 3.51 and 3.40 µg/ml (4 and 72 h, respectively). Racemic PZQ and trans-4-OH-PZQ resulted in an IC50 of 0.03 µg/ml and 1.47 µg/ml both at 4 and 72 h, respectively. In vivo, R-PZQ was the most potent drug with worm burden reductions (WBRs) of 98.5, 75.6 and 73.3% at 125.0, 62.5 and 31.0 mg/kg, respectively. A single oral dose of 250.0 mg/kg PZQ resulted in a WBR of 99.3%. S-PZQ was highly active in vivo at 250.0 and 500.0 mg/kg with WBRs of 83.0 and 94.1%, respectively. The lowest tested dose of S-PZQ, 125.0 mg/kg, showed moderate activity (WBR of 46.7%). The calculated ED50 for R- and S-PZQ were 24.7 and 127.6 mg/kg, respectively, with a corresponding eudysmic ratio of 5.17. CONCLUSION: Our data support the theory of R-PZQ driving the antischistosomal activity. Interestingly, also S-PZQ proved to possess a significant activity towards S. haematobium, particularly in vivo.
Asunto(s)
Praziquantel/análogos & derivados , Praziquantel/farmacología , Schistosoma haematobium/efectos de los fármacos , Esquistosomicidas/farmacología , Animales , Cricetinae , Humanos , Concentración 50 Inhibidora , Masculino , Mesocricetus , Praziquantel/química , Praziquantel/metabolismo , Praziquantel/uso terapéutico , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis Urinaria/tratamiento farmacológico , Esquistosomiasis Urinaria/parasitología , Esquistosomiasis mansoni/tratamiento farmacológico , Esquistosomicidas/metabolismo , Esquistosomicidas/uso terapéutico , EstereoisomerismoRESUMEN
After more than 40 years of use, Praziquantel (PZQ) still remains the drug of choice for the treatment of intestinal and urogenital schistosomiasis. Its anti-parasitic activity resides primarily in the (R)-enantiomer. Hitherto neither the molecular target nor the pharmacokinetic-pharmacodynamic relationship have been fully elucidated. Here we investigated the efficacy and pharmacokinetics of PZQ in the Schistosoma mansoni mouse model to determine the key factors that drive its efficacy. Dose-response studies with racemic PZQ with or without addition of an irreversible pan-cytochrome P450 (CYP) inhibitor, 1-aminobenzotriazole (ABT), were performed. In addition, efficacy of PZQ in the presence of the CYP inducer, dexamethasone (DEX), was determined. Plasma samples were obtained by tail vein bleeding at 4 time points. The (R)-PZQ levels were determined using a LC-MS/MS method. Non-compartmental pharmacokinetic analysis was performed using PKsolver. In addition, experiments using an enhanced in vitro assay were conducted. We found that the use of ABT increased (R)-PZQ plasma exposures in the systemic circulation by ~10 to 20 fold but the latter were not predictive of efficacy. The use of DEX decreased plasma exposures of (R)-PZQ in the systemic circulation by ~10 fold without reducing efficacy. We extrapolated the (R)-PZQ concentrations in mouse portal vein / mesenteric veins from the systemic exposures and found that a free exposure of (R)-PZQ of ~ 20 µM*h in the portal vein was needed to obtain a worm burden reduction >60%. It is suggested that the high (R)-PZQ concentrations available before the hepatic first pass metabolism drive the efficacy against S. mansoni adult worms residing in the mesenteric veins. It is then possible that the current dosing regimen of 40 mg/kg in preventive chemotherapy programs may provide suboptimal concentrations in low-weight patients such as children, due to smaller total amounts of drug administered, and may consequently result in lower cure rates.
Asunto(s)
Antihelmínticos/farmacología , Antihelmínticos/farmacocinética , Praziquantel/farmacología , Praziquantel/farmacocinética , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis mansoni/tratamiento farmacológico , Animales , Antihelmínticos/administración & dosificación , Quimioprevención/métodos , Cromatografía Liquida , Dexametasona/administración & dosificación , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Activadores de Enzimas/administración & dosificación , Inhibidores Enzimáticos/administración & dosificación , Ratones , Plasma/química , Praziquantel/administración & dosificación , Esquistosomiasis mansoni/prevención & control , Espectrometría de Masas en Tándem , Factores de Tiempo , Triazoles/administración & dosificaciónRESUMEN
The extensive use of praziquantel against schistosomiasis raises concerns about drug resistance. New therapeutic alternatives targeting critical pathways within the parasite are therefore urgently needed. Hemozoin formation in Schistosoma presents one such target. We assessed the in vitro antischistosomal activity of pyrido[1,2-a]benzimidazoles (PBIs) and investigated correlations with their ability to inhibit ß-hematin formation. We further evaluated the in vivo efficacy of representative compounds in experimental mice and conducted pharmacokinetic analysis on the most potent. At 10 µM, 48/57 compounds resulted in >70% mortality of newly transformed schistosomula, whereas 37 of these maintained >60% mortality of adult S. mansoni. No correlations were observed between ß-hematin inhibitory and antischistosomal activities against both larval and adult parasites, suggesting possible presence of other target(s) or a mode of inhibition of crystal formation that is not adequately modeled by the assay. The most active compound in vivo showed 58.7 and 61.3% total and female worm burden reduction, respectively. Pharmacokinetic analysis suggested solubility-limited absorption and high hepatic clearance as possible contributors to the modest efficacy despite good in vitro activity. The PBIs evaluated in this report thus merit further optimization to improve their efficacy and to elucidate their possible mode of action.
Asunto(s)
Bencimidazoles/farmacología , Piridinas/farmacología , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis mansoni/tratamiento farmacológico , Esquistosomicidas/farmacología , Animales , Bencimidazoles/síntesis química , Bencimidazoles/farmacocinética , Modelos Animales de Enfermedad , Femenino , Hemoproteínas/antagonistas & inhibidores , Hemoproteínas/biosíntesis , Concentración 50 Inhibidora , Ratones , Praziquantel/farmacología , Piridinas/síntesis química , Piridinas/farmacocinética , Schistosoma mansoni/crecimiento & desarrollo , Schistosoma mansoni/metabolismo , Esquistosomiasis mansoni/parasitología , Esquistosomicidas/síntesis química , Esquistosomicidas/farmacocinética , Relación Estructura-ActividadRESUMEN
BACKGROUND: Treatment options for infections with soil-transmitted helminths (STH) - Ascaris lumbricoides, Trichuris trichiura and the two hookworm species, Ancylostoma duodenale and Necator americanus - are limited despite their considerable global health burden. The aim of the present study was to test the activity of an openly available FDA library against laboratory models of human intestinal nematode infections. METHODS: All 1,600 drugs were first screened against Ancylostoma ceylanicum third-stage larvae (L3). Active compounds were scrutinized and toxic compounds, drugs indicated solely for topical use, and already well-studied anthelmintics were excluded. The remaining hit compounds were tested in parallel against Trichuris muris first-stage larvae (L1), Heligmosomoides polygyrus third-stage larvae (L3), and adult stages of the three species in vitro. In vivo studies were performed in the H. polygyrus and T. muris mice models. RESULTS: Fifty-four of the 1,600 compounds tested revealed an activity of > 60 % against A. ceylanicum L3 (hit rate of 3.4 %), following incubation at 200 µM for 72 h. Twelve compounds progressed into further screens. Adult A. ceylanicum were the least affected (1/12 compounds active at 50 µM), while eight of the 12 test compounds revealed activity against T. muris L1 (100 µM) and adults (50 µM), and H. polygyrus L3 (200 µM). Trichlorfon was the only compound active against all stages of A. ceylanicum, H. polygyrus and T. muris. In addition, trichlorfon achieved high worm burden reductions of 80.1 and 98.9 %, following a single oral dose of 200 mg/kg in the T. muris and H. polygyrus mouse model, respectively. CONCLUSION: Drug screening on the larval stages of intestinal parasitic nematodes is feasible using small libraries and important given the empty drug discovery and development pipeline for STH infections. Differences and commonalities in drug activities across the different STH species and stages were confirmed. Hits identified might serve as a starting point for drug discovery for STH.